MUC16 elevation

P=N/A, N=797, Active, not recruiting, AGO Study Group | Trial completion date: Apr 2024 --> Feb 2025 | Trial primary completion date: Apr 2024 --> Dec 2024

P1/2, N=72, Recruiting, Sham Sunder Kakar | Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2025 --> Nov 2026

PLFGT usually presents as gynecological symptoms and solid masses in pelvis. Surgery or biopsy was the way to obtain the pathologic diagnosis, and combination chemotherapy is the efficient method for PLFGT. Making an accurate preoperative diagnosis is of paramount importance to avoid radical gynecologic surgery.

In this study we applied a net reclassification approach to assess the use of MMP index to rescue those cases where low CA125 incorrectly excludes cancer diagnoses, or where benign disease is incorrectly assessed as "high risk" due to elevated CA125. Reclassification of such patients is of significant value to assist in the timely and accurate referral for patients where CA125 titer is uninformative.

P=N/A, N=2640, Recruiting, Mayo Clinic | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

Progression-free survival in the CA125-increased group, defined by an increase of 0.0067%/day using receiver operating characteristic curve analysis, was significantly poorer among patients with peritoneal metastases. In conclusion, this study highlights that CA125 kinetics can serve as an early predictor for the progression of peritoneal metastasis during TAX/RAM treatment.

P1/2, N=155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Jan 2025

Elevated CA 19-9 is associated with decreased PFS in patients with CRPM. While traditionally CEA is the main tumor marker assessed in colon cancer, we found that CA 19-9 may better inform preoperative risk stratification for poor oncologic outcomes in patients with CRPM. However, prospective studies are required to confirm this association.

Correlation analysis revealed that APTT (r= -0.207) and TT (r = -0.174) were negatively correlated with the level of CA125. The shortening of CA125-related APTT and TT indicates that it is meaningful to detect coagulation parameters of patients with elevated CA125 levels early, dysmenorrhea and menorrhagia, and maybe further discover the hypercoagulability and prevent the occurrence of thrombus in adenomyosis.

This should be considered as one of the differential diagnoses for ovarian cancer. Understanding the PET/CT features of MS can facilitate the attainment of an accurate diagnosis before surgery.

Cytokine analysis showed elevated interleukin (IL) levels, especially IL-6 in pleural effusion. Treatment with immunosuppressive therapy resulted in reduced cancer antigen (CA) 125 levels and decreased effusion volume, demonstrating a positive response to intervention in this case of PPMS.

Preoperative CA-125 was elevated in nearly 80% of high-risk early-stage ovarian cancer patients. Pre-chemotherapy CA-125 was associated with recurrence-free and overall survival; however, preoperative CA-125 was not prognostic.

P1/2, N=72, Not yet recruiting, Sham Sunder Kakar | Trial primary completion date: Nov 2024 --> Nov 2025

P2, N=20, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting

CONCLUSIONS A 10-year follow-up of patients with uterine sarcoma indicates that age above 60 years at diagnosis and high p53 expression and elevated CA125 levels before treatment can be independent prognostic factors. The high diagnostic sensitivity of sTNF RI and VEGF suggests the possibility of using these biomarkers in the early diagnosis of uterine sarcomas.

P3, N=418, Recruiting, ImmunoGen, Inc.

In a real-world setting, niraparib maintenance treatment in patients with non-gBRCA1/2 mutated recurrent platinum-sensitive ovarian cancer showed effectiveness comparable with published phase III studies and acceptable safety. Individualized dosing is essential to minimize adverse events. CA125 levels at start of niraparib treatment may help to estimate the individual prognosis.

Elevated preoperative serum CEA, CA-125, and CA19-9 levels exhibited poor overall survival and recurrence-free survival in cervical adenocarcinoma patients. Combined preoperative serum CA-125 and CA19-9 independently predicted distant metastasis in patients with endocervical adenocarcinoma.

P2, N=390, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026

Overall, 13 patients were identified. Median age was 48 (range 22-81). Eleven patients (11/13, 84.6%) had elevated ca-125 at time of diagnosis, with a median of 300 U/mL (range 9-1834 U/mL).

P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center

P1, N=73, Active, not recruiting, Mayo Clinic | Trial completion date: Oct 2023 --> Jun 2025 | Trial primary completion date: Oct 2023 --> Jun 2024

In postmenopausal women with elevated CA-125 serum levels and an adnexal mass suspicious for malignancy at ultrasound (US), ascites and pleural effusion, surgery, and histopathological examination are necessary. MS is a diagnostic option, with an excellent prognosis after exeresis of the mass.

Our findings provide valuable insights into the utilization patterns and clinical implications of CA-125 testing in ovarian and endometrial cancer diagnosis. While CA-125 remains a prominent tumor marker, its interpretation should consider age, gender, and clinical context. The study emphasizes the potential benefits of integrating additional markers and imaging modalities to enhance diagnostic accuracy. These findings contribute to optimizing the use of CA-125 testing for early detection and management of gynecological malignancies, thereby improving patient outcomes.

Positive/elevated CA125 level led to poor prognosis. Furthermore, younger age, low grade, early FIGO stage and localized SEER stage were significant predictors for improved OS.

CA125 also had strong predictive value for the prognosis of different ICC subgroups, including patients without lymph node metastasis and with elevated carbohydrate antigen 19-9 levels. Preoperative elevated serum CA125 level is a noninvasive, simple, and reliable indicator of the prognosis of ICC patients after hepatectomy.

P2, N=160, Suspended, University of Chicago | Trial completion date: Feb 2023 --> Feb 2025 | Trial primary completion date: Feb 2023 --> Feb 2025

P2, N=168, Recruiting, InxMed (Shanghai) Co., Ltd.

Lymphadenectomy can be omitted in patients with Endometrioid carcinoma that do not have any of the following risk factors: high-grade tumor, elevated Ca 125 (>28), and tumor volume on MRI greater than 25 cm . Tumor volume might predict the state of lymph nodes in EC and it could give information regarding surgical management.

SCCOHT is a rare and aggressive ovarian cancer, with a poor prognosis, and information on adequate treatment for this cancer is lacking. The testing of mutations in SMARCA4 is crucial for an accurate diagnosis and may lead to new treatment options. Harmonization and international collaboration to obtain high-quality data on diagnostic investigations, treatment, and outcome are warranted to be able to develop international treatment guidelines to improve the survival chances of young women with SCCOHT.

Therefore, she was started on lenvatinib and pembrolizumab infusion...Given the negative stroke work up, patient received high-dose dexamethasone as her symptoms could be mimicking MG... It is important to maintain a high index of suspicion for IrAEs, including rare neurologic toxicities such as ICI-induced MG, as delayed and inappropriate interventions are associated with increased morbidity and mortality.

Both the DCA curves of the training set and the validation set showed that the proposed predictive model had good clinical applicability. Older age, male, glucocorticoid therapy resistance, not complicated with ILD and arthralgia, elevated CA125, positive anti-TIF1-γ antibody, decreased LYM count are risk factors for malignancy in PM/DM patients, and the established nomogram model shows good predictive ability.

P1, N=73, Active, not recruiting, Mayo Clinic | Trial completion date: Jun 2025 --> Oct 2023 | Trial primary completion date: Jun 2023 --> Oct 2023

P2, N=300, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

Conclusions This case highlights the need to consider ependymoma as a potential differential diagnosis in ovarian or peritoneal malignancy in order to provide appropriate clinical management. Despite benign morphology, these tumors may behave aggressively.

P1/2, N=72, Not yet recruiting, Sham Sunder Kakar | Initiation date: Mar 2023 --> Aug 2023

At multivariable analysis, age (p = 0.001), FIGO stage (p = 0.002), fertility-sparing surgery (p = 0.001), invasive implants (p = 0.042), and tumor spillage (p = 0.031) appeared significantly associated with recurrence. Endophytic and exophytic patterns in borderline ovarian tumors show superimposable recurrence rates and disease-free survival.